- Home
- CYBN vs NVX Comparison
CYBN vs NVX Comparison
Compare CYBN & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- NVX
- Stock Information
- Founded
- CYBN 2019
- NVX 2012
- Country
- CYBN Canada
- NVX Australia
- Employees
- CYBN N/A
- NVX N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- NVX Industrial Machinery/Components
- Sector
- CYBN Health Care
- NVX Miscellaneous
- Exchange
- CYBN Nasdaq
- NVX Nasdaq
- Market Cap
- CYBN 176.5M
- NVX 204.1M
- IPO Year
- CYBN N/A
- NVX N/A
- Fundamental
- Price
- CYBN $6.07
- NVX $1.62
- Analyst Decision
- CYBN Strong Buy
- NVX
- Analyst Count
- CYBN 3
- NVX 0
- Target Price
- CYBN $85.00
- NVX N/A
- AVG Volume (30 Days)
- CYBN 673.9K
- NVX 465.6K
- Earning Date
- CYBN 11-12-2025
- NVX 01-01-0001
- Dividend Yield
- CYBN N/A
- NVX N/A
- EPS Growth
- CYBN N/A
- NVX N/A
- EPS
- CYBN N/A
- NVX N/A
- Revenue
- CYBN N/A
- NVX $5,931,433.00
- Revenue This Year
- CYBN N/A
- NVX $165.90
- Revenue Next Year
- CYBN N/A
- NVX $1,344.85
- P/E Ratio
- CYBN N/A
- NVX N/A
- Revenue Growth
- CYBN N/A
- NVX N/A
- 52 Week Low
- CYBN $4.81
- NVX $0.81
- 52 Week High
- CYBN $13.88
- NVX $2.73
- Technical
- Relative Strength Index (RSI)
- CYBN 45.10
- NVX 64.60
- Support Level
- CYBN $5.72
- NVX $1.20
- Resistance Level
- CYBN $6.52
- NVX $1.45
- Average True Range (ATR)
- CYBN 0.30
- NVX 0.12
- MACD
- CYBN 0.05
- NVX 0.02
- Stochastic Oscillator
- CYBN 38.48
- NVX 64.00
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.